Enable® Aortic Sutureless Bioprosthesis Evaluation

N/ACompletedNCT01720342

Medtronic Cardiac Rhythm and Heart Failure225 enrolled

Overview

The EASE Enable study is intended to collect additional data on the clinical outcomes of the Medtronic Enable® Aortic Bioprosthesis in "real world" patients.

The EASE Enable study is intended to characterize the clinical performance of the Medtronic Enable® aortic bioprosthesis in a post-market real-world setting. This is a Non-randomized, prospective, non-interventional multi-center post-market release (PMR) study. Up to 800 subjects will be enrolled at up to 40 centers in Europe. After aortic valve replacement with the Enable® aortic bioprosthesis, each patient will have routine follow-up visits at the following intervals: at 30 days post-implant (at 30 days post-implant or prior to hospital discharge, whatever comes first), within 6 months following implantation, 1 year and annually thereafter up to 5 years post-implant.

Study Type

OBSERVATIONAL

Enrollment

225

Conditions

Aortic Valve Stenosis Aortic Valve Insufficiency

Interventions

Aortic Valve Replacement surgeryPROCEDURE

Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with aortic valve stenosis, aortic valve insufficiency or a combination of the two. * Patient requires replacement of his/her native aortic valve with a bioprosthesis with or without concomitant procedures. * Patient is above the minimum age as required by local regulations to be participating in a clinical study. * Patient is willing to return to the implant site for follow-up visits. * Patient has been adequately informed of this clinical study and is willing to sign the patient Data Release Form. Exclusion Criteria: * Patient requires replacement of two or more valves. * Patient who underwent previous aortic valve replacement (AVR). * Patient with native bicuspid aortic valve. * Patient with active endocarditis or other systemic infection. * Patient dilatation of the ascending aorta, deformations or irregular aortic annulus or ascending aorta geometry as seen via preoperative imaging.

Locations (17)

Centre Hospitalier Régional Universitaire de Lille (CHRU)

Lille, France

Centre Hospitalier Universitaire de Saint-Etienne Hôpital Nord

Saint-Etienne, France

Outcomes

Primary Outcomes

Change from Baseline in Clinical performance during implant procedure, at 30 days post-implant (or prior to hospital discharge, whatever comes first), within 6 months post-operation, 1 year and annually thereafter up to 5 years post-procedure.

The early and late (up to five years) clinical performance of the Enable® aortic bioprosthesis will be characterized. Measures of clinical performance will include hemodynamic performance by echocardiography, New York Heart Association (NYHA) Functional Classification and safety (SAEs, ADEs, SADEs).

Time frame: During implant procedure, at 30 days post-implant (or prior to hospital discharge, whatever comes first), within 6 months post-operation, 1 year and annually thereafter up to 5 years post-procedure.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.